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Abstract
Background: The timeliness of HIV diagnosis and the initiation of antiretroviral treatment are major determinants of survival
for HIV-infected people. Injection drug users (IDUs) are less likely than persons in other transmission categories to seek early
HIV counseling, testing, and treatment. Our objective was to estimate the proportion of IDUs with a late HIV diagnosis (AIDS
diagnosis within 12 months of HIV diagnosis) and determine the factors associated with disease progression after HIV
diagnosis.
Methodology/Principal Findings: Using data from 33 states with confidential name-based HIV reporting, we determined
the proportion of IDUs aged $13 years who received a late HIV diagnosis during 1996–2004. We used standardized Kaplan-
Meier survival methods to determine differences in time of progression from HIV to AIDS and death, by race/ethnicity, sex,
age group, CD4+ T-cell count, metropolitan residence, and diagnosis year. We compared the survival of IDUs with the
survival of persons in other transmission categories. During 1996–2004, 42.2% (11,635) of 27,572 IDUs were diagnosed late.
For IDUs, the risk for progression from HIV to AIDS 3 years after HIV diagnosis was greater for nonwhites, males and older
persons. Three-year survival after HIV diagnosis was lower for IDU males (87.3%, 95% confidence interval (CI), 87.1–87.4)
compared with males exposed through male-to-male sexual contact (91.6%, 95% CI, 91.6–91.7) and males exposed through
high-risk heterosexual contact (HRHC) (91.9%, 95% CI, 91.8–91.9). Survival was also lower for IDU females (89.5%, 95% CI,
89.4–89.6) compared to HRHC females (93.3%, 95% CI, 93.3–93.4).
Conclusions/Significance: A substantial proportion of IDUs living with HIV received their HIV diagnosis late. To improve
survival of IDUs, HIV prevention efforts must ensure early access to HIV testing and care, as well as encourage adherence to
antiretroviral treatment to slow disease progression.
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Introduction
Although mortality has decreased significantly and the progno-
sis for HIV patients has improved since the introduction of highly
active antiretroviral therapy (HAART) [1–3], the survival of HIV-
infected injection drug users (IDUs) may not have improved as
much as for persons in other transmission categories. The
timeliness of HIV diagnosis and the initiation of HAART are
major determinants of survival for HIV-infected people [4]. There
is growing evidence that IDUs not only have suboptimal access
and adherence to HAART [5,6] but also tend to begin
antiretroviral treatment at a more advanced stage of infection
[5,7]. There are significant public health benefits of early diagnosis
and treatment of HIV infection among IDUs. Reports show that
IDUs, who know that they are infected with HIV, are more likely
to protect their partners from infection reducing further the spread
of the virus [8,9]. An analysis of US population–based data
(including IDUs) showed that the survival of IDUs after HIV
diagnosis was shorter than that of persons in other transmission
categories [10]. Despite earlier research, no findings on late testing
and survival data specific to subpopulations of HIV-infected IDUs
have been published. We wished to determine whether demo-
graphic factors such as race/ethnicity, sex, and age affect
prognosis in the HAART era. Therefore, using data from the
national HIV/AIDS surveillance system of the Centers for Disease
Control and Prevention (CDC), we examined the proportions of
subpopulations of IDUs who received a late HIV diagnosis and the
determinants of disease progression and survival. Understanding
the problem of late HIV diagnosis and determinants of survival for
IDUs is important to the development and implementation of
HIV prevention efforts.
Methods
In 1994, CDC implemented a uniform system for national
surveillance of HIV infection integrated with AIDS surveillance,
and 25 states with confidential name-based HIV infection
reporting started submitting case reports to the CDC. Over time,
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additional areas implemented confidential name-based HIV
infection reporting and started submitting data to CDC. For our
analyses, data were available from 33 states (Alabama, Alaska,
Arizona, Arkansas, Colorado, Florida, Idaho, Indiana, Iowa,
Kansas, Louisiana, Michigan, Minnesota, Mississippi, Missouri,
Nebraska, Nevada, New Jersey, New Mexico, New York, North
Carolina, North Dakota, Ohio, Oklahoma, South Carolina, South
Dakota, Tennessee, Texas, Utah, Virginia, West Virginia,
Wisconsin, and Wyoming). We analyzed cases in adults and
adolescents, aged 13 years and older, for whom HIV diagnosis was
made during 1996–2004 and who were reported to CDC through
June 2007 from the 33 states. Persons with HIV infection were
defined as those who had received a diagnosis of HIV with or
without a diagnosis of AIDS at the time of HIV diagnosis. HIV
diagnosis was considered late if an AIDS diagnosis was made ,12
months after the HIV diagnosis [11]. HIV diagnosis was
considered concurrent when AIDS diagnosis was made at or
within the same calendar month of HIV diagnosis. AIDS is
defined by a CD4+ T-cell count ,200 cells/mL or by an AIDS-
defining illness.
Progression from HIV Diagnosis to AIDS
To understand patterns in diseases progression, we examined
the time from the diagnosis of HIV infection to the time of
diagnosis of AIDS among the adolescent and adult HIV-infected
IDUs who received a diagnosis of HIV infection during 1996–
2004. First, we determined the proportion of IDUs whose
diagnosis of AIDS was made within 12 months after HIV
diagnosis; then we compared the proportion of IDUs with the
proportions of persons in other transmission categories (chi-square
test, P,.05). We used the hierarchical transmission categories of
male-to-male sexual contact, injection drug use, male-to-male
sexual contact and injection drug use; and high-risk heterosexual
contact (heterosexual contact with a person known to have, or to
be at high risk for, HIV infection).
We used a standardized Kaplan-Meier survival method [12] to
determine the time from a diagnosis of HIV infection to a
diagnosis of AIDS among IDUs, by race/ethnicity, sex, age group,
metropolitan residence, and diagnosis year. Cases of HIV were
followed up for diagnosis of AIDS through December 31, 2005
(censor date), for AIDS diagnoses reported through June 30, 2007
(allowing 2.5 years for a diagnosis of AIDS to be reported). For
individuals who were event free (no AIDS diagnosis reported) at
the censor date, it was assumed that the disease had not progressed
to AIDS. Data on persons who died during the follow-up period
were censored at date of death. The completeness of AIDS and
HIV (not AIDS) case reporting was estimated at more than 85%
[11]. We calculated the proportion of IDUs whose infection did
not progress to AIDS. Race/ethnicity was categorized as white,
black, Hispanic, Asian/Pacific Islander, and American Indian/
Alaska Native. The categories for age were 13–24, 25–34, 35–44,
45–54, and 55 years and older. The categories for metropolitan
residence were metropolitan statistical areas of,50,000, 50,000 to
499,999, 500,000 to 2,499,999 and .2.5 million. Estimates were
adjusted for all other factors in our analyses. The date of diagnosis
was missing or incomplete for 413 of 27,985 (1.5%) HIV-infected
IDUs; the data for these 413 persons were excluded from analyses.
Survival after HIV Diagnosis
Using data from 33 states, we determined the survival of
adolescents and adults for whom HIV infection was diagnosed
during 1996–2004. Cases were followed up through December 31,
2005 (i.e., censored), for deaths reported through June 30, 2007
(allowing 2.5 years for deaths to have been reported). Individuals
without a death report at censoring date were assumed to be alive.
First, we determined survival among IDUs and then compared
their survival with the survival of persons in other transmission
categories. To determine the factors associated with survival
among IDUs, we stratified IDUs by race/ethnicity, sex, age group,
CD4+ T-cell count, concurrent diagnosis of HIV and AIDS (this
variable measures severity of disease at diagnosis), metropolitan
residence, and diagnosis year. The categories for CD4+ T-cell
count at HIV diagnosis (first CD4+ T-cell count reported within 6
months after diagnosis) were: ,50, 50–99, 100–199, and $200/
mL (categories used in earlier prognostic models [13]); CD4+ T-cell
count was missing for 68.0% of cases. We present the 1-year and
3-year survival estimates by using directly standardized Kaplan-
Meier techniques [12]. Significant differences between groups
were assessed by determining whether the 95% confidence
intervals overlapped. Of all 236,021 HIV cases diagnosed during
1996–2004, 3,334 (1.4%) and of 27,478 HIV-infected IDUs, 451
(1.6%) respectively did not have complete information on date of
diagnosis, and were excluded from analyses.
Results
Late HIV Diagnosis and Progression from HIV Diagnosis
to AIDS
Of the 27,572 cases of HIV infection diagnosed among IDUs in
the 33 states during 1996–2004, HIV infection in 57.8% did not
progress to AIDS within 12 months after HIV diagnosis (Table 1,
see column 3). In other words, in 42.2% of IDUs, HIV infection
progressed to AIDS within 12 months, and these IDUs were
therefore considered to have received a late diagnosis. A
significantly larger proportion of IDUs received a late diagnosis,
compared with persons in other transmission categories: men who
have sex with men [MSM], 39.8%; MSM who were also IDUs,
38.6%; and heterosexual adults at high risk, 36.6% (P,.0001; data
not shown).
Among HIV-infected IDUs, a larger proportion of males
(45.5%) than females (36.1%) received a late diagnosis (Table 1).
By race/ethnicity, the largest proportion of those with a late
diagnosis comprised Asians/Pacific Islanders (52.7%), followed by
American Indians/Alaska Natives (50.1%), whites (43.0%),
Hispanics (42.7%), and blacks (42.3%). The proportions of
persons with a late diagnosis increased with age—from 20.2% of
those aged 13–24 to 53.4% of those aged 55 and older.
At 3 years, HIV infection in IDUs was least likely to have
progressed to AIDS in whites, compared with blacks, Hispanics,
Asians/Pacific Islanders, and American Indians/Alaska Natives
(Table 1, column 5). HIV infection did not progress to AIDS in
46.2% of males (95% CI, 45.9–46.6) compared with 54.9% of
females (95% CI, 54.5–55.2). AIDS was significantly more likely to
develop within 3 years among older IDUs than among younger
IDUs. The proportion of IDUs in whom HIV infection did not
progress to AIDS did not differ substantially by metropolitan
residence. The proportion of IDUs in whom HIV infection did not
progress to AIDS was larger in later years (2002 and 2001) than in
1996.
Survival after HIV Diagnosis
Of 232,685 persons in 33 states who received a diagnosis of
HIV infection (with or without concurrent AIDS) during 1996–
2004, 27,027 (11.6%) had IDU-associated HIV diagnoses. Fewer
IDUs, compared with persons who had other identified risk
factors, survived 3 years after HIV diagnosis (Table 2, see column
3 for 1-year and column 5 for 3-year survival). Of 27,027 IDUs in
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33 states who received a diagnosis of HIV infection during 1996–
2004, a total of 5,896 died by the end of 2005. Twenty-five percent
of IDUs were diagnosed with HIV and AIDS at the same time,
and among those IDUs 38.2% had very low CD4+ T-cell counts at
HIV diagnosis (,50 cells/mL) (data not shown). Survival was
substantially shorter for IDUs with concurrent diagnosis of HIV
and AIDS compared with IDUs who had an HIV diagnosis (not
AIDS) only (Table 3). Survival among IDUs did not differ
substantially by sex. The analysis of the survival of IDUs by race/
ethnicity, at 3 years revealed that smaller proportions of American
Indians/Alaska Natives (82.8%) and blacks (85.8%, 95% CI, 85.6–
85.9) had survived. Fewer older IDUs survived 1 and 3 years after
HIV diagnosis compared with those who received a diagnosis
when they were younger. Survival was longer for IDUs with
higher CD4+ T-cell counts, but this information was missing for
68.0% of patients (most of whom had received a diagnosis of HIV
without AIDS). Fewer of the IDUs living in metropolitan areas,
compared with nonmetropolitan areas, survived 1 and 3 years
after HIV diagnosis. In later years (2002 or 2001), compared with
1996, a slightly larger proportion of IDUs had survived.
Discussion
Despite the well-known benefits of early detection and the
availability of treatment for HIV infection, 42.2% of HIV-infected
IDUs received a diagnosis of AIDS within 12 months after receiving
a diagnosis of HIV infection. IDUs whose diagnosis is made late in
the course of HIV infection may unknowingly transmit infection
and once diagnosed may have worse outcomes. In our analysis we
found that survival among IDUs was shorter than among other HIV
risk groups. The proportion of IDUs who did not progress to AIDS
3 years after HIV infection was lower among men. IDUs with a
diagnosis of HIV at older ages or with more severe disease (lower
CD4+ T-cell count at AIDS diagnosis) had shorter survival.
Table 1. Percentage of IDUs with HIV diagnosis who did not progress to AIDS in 1996–2004, 33 U.S. States.
Race/ethnicity No %
Percent without AIDS 1 year
after HIV diagnosis
Percent without AIDS 3 years after
HIV diagnosis
% 95% CI % 95% CI
White 7,229 26.2 57.0 56.5 , 57.5 49.9 49.6 , 50.2
Black 15,616 56.6 57.7 57.1 , 58.2 48.9 48.5 , 49.2
Hispanic 4,456 16.2 57.3 56.8 , 57.8 48.3 47.8 , 48.8
Asian/Pacific Islander 57 0.2 47.3 — 39.3 —
American Indian/Alaska Native 214 0.8 49.9 49.7 , 50.0 41.4 —
Sex
Male 17,927 65.0 54.5 54.1 , 55.0 46.2 45.9 , 46.6
Female 9,645 35.0 63.9 63.4 , 64.4 54.9 54.5 , 55.2
Age (years)
13–24 1,339 4.9 79.8 79.5 , 80.1 71.7 —
25–34 5,942 21.6 64.8 64.1 , 65.5 55.9 55.5 , 56.4
35–44 11,718 42.5 55.9 55.2 , 56.5 47.3 46.9 , 47.6
45–54 7,148 25.9 51.7 51.1 , 52.3 43.2 42.7 , 43.7
$55 1,425 5.2 46.6 45.9 , 47.3 38.2 37.6 , 38.8
Metropolitan residence
,50,000 2,502 9.1 58.1 57.1 , 59.0 49.8 49.5 , 50.1
50,000–499,999 4,278 15.5 57.6 57.1 , 58.2 50.5 50.0 , 50.9
500,000–2,499,999 14,096 51.1 57.4 56.9 , 58.0 49.0 48.7 , 49.4
$2.5 million 6,696 24.3 57.5 56.8 , 58.2 48.0 47.7 , 48.3
Diagnosis year
1996 3,315 12.0 54.1 53.2 , 55.0 46.2 45.6 , 46.8
1997 2,676 9.7 54.4 53.3 , 55.5 46.6 45.8 , 47.4
1998 2,221 8.1 55.1 54.2 , 56.0 48.5 47.9 , 49.2
1999 2,834 10.3 56.3 55.2 , 57.4 47.3 46.8 , 47.8
2000 3,289 11.9 56.9 55.9 , 57.8 48.2 47.6 , 48.8
2001 4,430 16.1 59.4 58.4 , 60.4 51.0 50.5 , 51.5
2002 3,449 12.5 59.9 58.9 , 61.0 50.7 49.8 , 51.7
2003 2,872 10.4 59.2 57.9 , 60.4
2004 2,486 9.0 56.8 55.6 , 57.9
Total 27,572 100.0 57.8 57.5 , 58.2 49.3 49.1 , 49.6
Estimates are from standardized Kaplan-Meier analyses, adjusted for all other factors shown in the table. Data reported to CDC through June 2007. Dash indicates data
not presented because the variance for the estimate is zero.
doi:10.1371/journal.pone.0004445.t001
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Our results were consistent with earlier findings of shorter
survival after HIV diagnosis among IDUs compared with persons
in other transmission categories [10]. Disparities between risk
groups in the receipt of, or the adherence to, treatment might
explain the observed differences in survival. Numerous studies
have documented that the prescription of, and the adherence to,
HAART is lower among IDUs than among persons who do not
use drugs [14–16] because of IDUs’ disadvantaged social situation,
financial difficulties, and lack of family and social support [17–19].
Even in settings that provide free HIV treatment, low rates of
utilization among eligible IDUs have been reported [20]. The use
of HAART has been shown to be less common among active
IDUs who do not have symptomatic diseases and thus have less
contact with health care providers [5]. The strategies that have
improved access and adherence to antiretroviral medications
among HIV-infected IDUs include directly observed therapy,
access to medical services without appointment, on-site pharma-
cists (at medical clinics), and improved access to addiction
treatment [15,21]. Information on treatment and type of health
insurance, which might be related to receipt of treatment, was not
available. In addition, deaths due to other causes (end-stage liver
disease, bacterial infections), which are more common among
IDUs than other risk groups, may play a role in the shorter
survival of IDUs [22]. Future studies should assess whether the
receipt of, or the adherence to, treatment can explain poorer
survival of IDUs.
Shorter survival among IDUs may also be linked to late testing.
A large proportion of IDUs learned of their HIV infection late in
the course of disease, reducing optimal benefit from new
therapeutic strategies, which remains a major public health issue.
In an HIV testing study of persons at high risk for HIV infection,
researchers found that the main reasons for not being tested were
denial of HIV risk factors and fear of being HIV-positive [23].
Efforts to test HIV-infected people as early as possible should be
made by increasing the awareness of HIV risk factors and
decreasing the number of missed opportunities for testing.
Addiction treatments and needle exchange programs are impor-
tant venues to offer testing for HIV-positive IDUs. Understanding
the psychological and social reasons for late testing among IDUs
could help public health officials develop initiatives to reduce
barriers to testing. CDC recommends routine testing in medical
settings of all persons aged 13–64 years [24] to reduce the number
of persons unaware of their HIV infection and diagnose HIV
infection earlier in the disease process.
Similar to earlier analyses [11], our analysis revealed a lower
probability of progression from HIV infection to AIDS within 1
year and within 3 years for female IDUs, compared with male
IDUs. This finding may be explained by prenatal tests and
gynecologic follow-up, which could increase the likelihood of HIV
testing among female IDUs [25]. Persons, including IDUs, who
receive a diagnosis of HIV infection at an older age are at
increased risk of progressing from HIV diagnosis to AIDS or death
within 1 and 3 years. Older age is a strong risk factor for disease
progression because older persons have diminished immune
function and more comorbidities [10,26,27]. In addition, our
results show that older IDUs were more likely to receive a late
diagnosis. As expected, CD4+ T-cell count at AIDS diagnosis was
a strong determinant of survival [13,28]. Guidelines for the use of
antiretroviral medications in adults and adolescents infected with
HIV type 1 recommend initiating treatment in patients with a
history of an AIDS-defining illness or with a CD4+ T-cell count of
,350 cells/mL [29]. Kohli et al. [22] reported that HIV-infected
IDUs who began taking HAART at a CD4+ T-cell count of .200
cells/mL survived longer than those who began taking HAART at
a CD4+ T-cell count of #200 cells/mL. Unfortunately, a
substantial proportion of IDUs in the United States received a
concurrent diagnosis of HIV and AIDS, and 38.2% of these
persons had very low CD4+T-cell counts at HIV diagnosis (,50
cells/mL).
Our analyses are subject to several limitations. Although our
data represent the largest set of available population-based data on
HIV-infected persons, the data from 33 states may not be
nationally representative, and it is not known whether the results
can be extrapolated to the United States as a whole. However, all
states and the District of Columbia have now implemented
confidential name-based HIV reporting. The increased number of
name-based reporting states will allow a more accurate description
of the size of the population of HIV-infected IDUs and the
Table 2. Survival of persons with HIV* diagnosis by transmission category in 1996–2004, 33 U.S. States.
Transmission category No %
Probability of surviving 1
year after HIV* diagnosis
Probability of surviving 3
years after HIV* diagnosis
% 95% CI % 95% CI
Male-to-male sexual contact 82,673 35.5 95.2 95.2 , 95.3 91.6 91.6 , 91.7
Injection drug use
Male 17,528 7.5 93.2 93.1 , 93.4 87.3 87.1 , 87.4
Female 9,498 4.1 95.1 95.0 , 95.3 89.5 89.4 , 89.6
Male-to-male sexual contact and injection drug use 7,616 3.3 95.5 95.5 , 95.6 90.7 90.6 , 90.8
High-risk heterosexual contact
Male 18,670 8.0 95.7 95.6 , 95.8 91.9 91.8 , 91.9
Female 33,708 14.5 96.8 96.7 , 96.9 93.3 93.3 , 93.4
Unknown/other
Male 38,837 16.7 92.4 92.3 , 92.5 88.1 88.1 , 88.2
Female 24,155 10.4 94.8 94.7 , 94.9 90.9 90.8 , 91.0
Total 232,685 100.0
*Diagnosis of HIV infection with or without a concurrent diagnosis of AIDS.
doi:10.1371/journal.pone.0004445.t002
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determinants of disease severity. Risk factor information was
missing for 27.1% of the persons with a diagnosis of HIV infection,
so the data could not be included in our analysis. We also found
that a large proportion of HIV-infected persons did not have a
reported CD4+ T-cell count, which may reflect a lack of access to
care or differences in reporting (e.g., state laws requiring
laboratories to report). Finally, special research should be
undertaken to better understand the reasons for late HIV testing
(routine surveillance does not collect information about the
reasons for late HIV testing).
In summary, we found that for large proportions of HIV-
infected IDUs, diagnosis was made late in the disease process and
Table 3. Survival of IDUs with HIV* diagnosis in 1996–2004, 33 U.S. States.
Race/ethnicity No %
Probability of surviving 1
year after HIV* diagnosis
Probability of surviving 3
years after HIV* diagnosis
% 95% CI % 95% CI
White 7,089 26.2 93.3 93.2 , 93.5 87.1 86.9 , 87.3
Black 15,312 56.7 92.8 92.6 , 93.0 85.8 85.6 , 85.9
Hispanic 4,360 16.1 94.3 94.2 , 94.5 88.1 88.0 , 88.3
Asian/Pacific Islander 57 0.2 97.9 — 97.9 —
American Indian/Alaska Native 209 0.8 94.1 — 82.8 —
Sex
Male 17,528 64.9 92.7 92.6 , 92.8 85.9 85.8 , 86.1
Female 9,498 35.1 93.8 93.7 , 93.9 87.1 87.0 , 87.2
Age (years)
13–24 1,332 4.9 98.4 98.3 , 98.5
25–34 5,893 21.8 95.9 95.8 , 96.0 91.1 91.0 , 91.2
35–44 11,508 42.6 93.4 93.2 , 93.6 86.7 86.5 , 86.9
45–54 6,924 25.6 91.6 91.3 , 91.8 82.3 82.1 , 82.5
$55 1,370 5.1 84.2 84.0 , 84.4 75.6 75.4 , 75.8
CD4+T-cell count within 6 months after AIDS diagnosis
,50 3,516 13.0 81.6 81.2 , 82.0 69.0 68.7 , 69.4
50–99 1,582 5.9 85.4 85.3 , 85.5 74.8 74.7 , 74.8
100–199 2,900 10.7 93.1 92.8 , 93.4 84.2 84.1 , 84.3
$200 643 2.4 95.8 95.7 , 95.8 89.2 89.1 , 89.2
Unknown 18,386 68.0 94.1 93.9 , 94.3 88.2 88.0 , 88.3
AIDS at HIV diagnosis
Yes 6,656 24.6 84.9 84.5 , 85.2 75.1 75.0 , 75.2
No 20,371 75.4 94.4 94.2 , 94.5 87.9 87.7 , 88.0
Metropolitan residence
,50,000 2,453 9.1 94.4 94.1 , 94.6 89.5 89.4 , 89.7
50,000–499,999 4,214 15.6 93.6 93.3 , 93.8 87.3 87.1 , 87.5
500,000–2,499,999 13,806 51.1 92.8 92.7 , 93.0 85.9 85.8 , 86.1
$2.5 million 6,554 24.2 93.3 93.0 , 93.5 86.5 86.4 , 86.7
Diagnosis year
1996 3,254 12.0 92.2 91.8 , 92.6 84.2 83.9 , 84.4
1997 2,629 9.7 93.0 92.7 , 93.4 85.4 85 , 85.8
1998 2,178 8.1 92.6 92.3 , 92.9 85.6 85.2 , 86.0
1999 2,769 10.2 93.2 92.9 , 93.6 86.2 85.9 , 86.5
2000 3,225 11.9 93.3 93.1 , 93.5 86.5 86.2 , 86.8
2001 4,325 16.0 93.4 93.2 , 93.6 87.2 86.9 , 87.5
2002 3,380 12.5 93.8 93.6 , 94.1 87.9 87.6 , 88.2
2003 2,822 10.4 93.9 93.6 , 94.2
2004 2,444 9.0 93.3 92.9 , 93.7
Total 27,027 100.0 92.8 92.7 , 92.9 85.9 85.8 , 86.0
Estimates are from standardized Kaplan-Meier survival analyses, adjusted for all other factors shown in the table.
*Diagnosis of HIV infection with or without a concurrent diagnosis of AIDS.
Dash indicates data not presented because the variance for the estimate is zero.
doi:10.1371/journal.pone.0004445.t003
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HIV infection progressed to AIDS within 3 years. Also, survival
among IDUs was shorter than among other HIV risk groups.
These findings suggest that public health and medical services
need to be improved to better target interventions for prolonging
the lifespan of IDUs living with HIV infection, in addition to
primary HIV prevention initiatives.
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